What are the best treatments for insomnia in patients with attention-deficit/hyperactivity disorder (ADHD) and why is insomnia more common in this population?

Best Treatments for Insomnia in ADHD Patients

Cognitive Behavioral Therapy for Insomnia (CBT-I) should be the first-line treatment for insomnia in adults with ADHD, followed by pharmacotherapy only if CBT-I fails, with the critical understanding that ADHD stimulant medications often improve rather than worsen insomnia in this population. 1

Why Insomnia is More Common in ADHD

Insomnia affects 43-80% of adults with ADHD compared to only 29% of the general population 2, 3. This dramatically higher prevalence stems from several interconnected mechanisms:

• Neurobiological overlap: ADHD and insomnia share dysregulation in arousal systems, dopaminergic pathways, and circadian rhythm control 3, 4
• Emotion regulation deficits: Adults with ADHD struggle to downregulate emotional arousal at bedtime, with limited access to effective regulation strategies being the strongest predictor of insomnia symptoms 5
• Combined subtype vulnerability: The combined ADHD presentation shows 80% insomnia prevalence versus 56% in inattentive subtype, suggesting hyperactivity/impulsivity directly interferes with sleep initiation 6, 2
• Bidirectional relationship: Sleep deprivation worsens inattention and emotional dysregulation, while evening hyperactivity prevents sleep onset, creating a self-perpetuating cycle 4, 7

Treatment Algorithm

Step 1: Initiate CBT-I (First-Line)

CBT-I is the only treatment with a strong recommendation from major guidelines 1. It combines:

• Sleep restriction therapy: Limit time in bed to actual sleep time, then gradually increase as efficiency improves
• Stimulus control: Strengthen bed-sleep association, establish consistent sleep-wake times
• Cognitive therapy: Address maladaptive beliefs about sleep
• Relaxation training: Counterarousal strategies
• Sleep hygiene education: As adjunct only, never standalone 8, 9

Delivery options include in-person, group, telehealth, or internet-based formats—all show efficacy 1, 9. Treatment typically requires 4-8 sessions with gradual improvement (not immediate like medications) 10.

Critical pitfall: Sleep hygiene alone is ineffective and potentially harmful if it delays referral to CBT-I 9. Patients may assume all behavioral treatments are similarly ineffective.

Step 2: Optimize ADHD Medication (Often Improves Sleep)

Contrary to common assumptions, stimulant treatment is associated with improved sleep quality and reduced insomnia in ADHD patients 11, 6, 2. This counterintuitive finding reflects that:

• Stimulants reduce daytime hyperactivity that interferes with evening wind-down
• Better daytime symptom control improves emotional regulation at bedtime
• Stable ADHD pharmacotherapy correlates with lower insomnia rates 6

Specific findings:

• Stimulants: Significantly improved sleep quality and reduced insomnia odds 11
• Atomoxetine: Linked to lower insomnia and circadian rhythm disorder odds 11
• Current stimulant users report lower insomnia scores than unmedicated ADHD patients 2

However, insomnia remains a treatment-emergent adverse effect in some patients:

• Mixed amphetamine salts: 40-45%
• Dasotraline: 35-45%
• Lisdexamfetamine: 10-19%
• Extended-release methylphenidate: 11% 3

Step 3: Add Pharmacotherapy if CBT-I Fails

Use shared decision-making discussing benefits, harms, and costs for short-term use only 1. The evidence-based sequence is:

First-line pharmacotherapy 8:

• Short-intermediate acting benzodiazepine receptor agonists (zolpidem, eszopiclone, zaleplon, temazepam) OR ramelteon
• Evidence: Eszopiclone, zolpidem, and suvorexant show small but significant improvements in sleep onset latency, total sleep time, and global outcomes 12, 1

Second-line (if first-line unsuccessful):

• Alternate BzRA or ramelteon

Third-line:

• Sedating antidepressants (trazodone, doxepin, mirtazapine)—especially when treating comorbid depression/anxiety 8
• Caution: Antidepressant use is significantly associated with increased insomnia risk in ADHD patients 11

Fourth-line:

• Combined BzRA/ramelteon plus sedating antidepressant

Critical safety considerations:

• FDA warns of dementia, fractures, driving impairment, and behavioral changes with hypnotics 1, 12, 1
• Recommend lower doses in women and older adults 1
• Intended for short-term use (4-5 weeks), though many patients continue long-term 1
• Evidence insufficient for long-term safety 1

Step 4: Adjunctive Interventions

Morning light therapy shows the strongest evidence among alternative treatments for ADHD-related sleep problems, with three systematic studies demonstrating significant effects 13. This is particularly relevant given circadian rhythm dysregulation in ADHD.

Melatonin has preliminary evidence but insufficient data in general ADHD populations 8, 13.

Key Clinical Considerations

Comorbidity burden: Insomnia in ADHD is strongly associated with:

• Mood disorders (42% prevalence)
• Anxiety disorders (27%)
• Personality disorders (39%)
• Substance use disorders (12%)
• Higher BMI and female sex 11, 6

Monitor closely: Reassess every few weeks until stable, then every 6 months due to high relapse rates 8. Use sleep diaries throughout treatment.

Quality of life impact: Insomnia disorder in ADHD correlates with worse health-related quality of life and greater ADHD symptom severity 6.

Avoid common errors:

• Don't withhold or discontinue stimulants assuming they cause insomnia—they often improve it 11, 6, 2
• Don't use sleep hygiene as standalone treatment 9, 10
• Don't delay CBT-I referral in favor of immediate pharmacotherapy 1